1.1.1.50: 3alpha-hydroxysteroid 3-dehydrogenase (Si-specific)

This is an abbreviated version, for detailed information about 3alpha-hydroxysteroid 3-dehydrogenase (Si-specific), go to the full flat file.

Reaction

a 3alpha-hydroxysteroid
+
NAD(P)+
=
a 3-oxosteroid
+
NAD(P)H
+
H+

Synonyms

3 alpha-hydroxysteroid dehydrogenase, 3 alphaHD, 3-alpha-HSD, 3alpha-HSD, 3alpha-HSD/CR, 3alpha-HSOR, 3alpha-hydroxysteroid dehydrogenase, 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase, 3alpha-hydroxysteroid oxido-reductase, 3alpha-hydroxysteroid oxidoreductase, 3alpha-hydroxysteroid-5beta-oxidoreductase activity, 3alpha-OR, 3alpha-oxidoreductase, 3alpha/3beta-hydroxysteroid dehydrogenase, 3alphaHSD, 3HSD, 5alpha-dihydroprogesterone 3alpha-hydroxysteroid oxidoreductase, AKR1C, AKR1C1-4, AKR1C17, AKR1C2, AKR1C3, AKR1C4, AKR1C9, aldo-keto reductase 1C2, bile-acid binding protein, chlordecone reductase, DD2, DD21, dihydrodiol dehydrogenase, HSD, HSD28, HSD29, hsdA, HSDH, hydroxyprostaglandin dehydrogenase, More, NAD(P)+-3alpha-hydroxysteroid dehydrogenase, NAD+-dependent 3alpha-HSD, NADP(H)-dependent 3alpha-HSD, NADPH:5alpha-dihydroprogesterone 3alpha-hydroxysteroid oxidoreductase, prostaglandin F2alpha-synthase, PT3HSD, sterognost 3alpha dehydrogenase, 3alpha-hydroxy steroid, type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase, type 3 3alpha-hydroxysteroid dehydrogenase, type 5 17beta-hydroxysteroid dehydrogenase, type I 3alpha-HSD

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.50 3alpha-hydroxysteroid 3-dehydrogenase (Si-specific)

Inhibitors

Inhibitors on EC 1.1.1.50 - 3alpha-hydroxysteroid 3-dehydrogenase (Si-specific)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1-Methylpyrrole acetic acid
-
-
11beta,17alpha,21-trihydroxy-4-pregnen-3,20-dione
-
-
11beta,21-dihydroxy-4-pregnen-3,20-dione
-
-
17,21-Dihydroxy-5alpha-pregnan-3,20-dione
-
-
17alpha,21-Dihydroxy-1,4-pregnadien-3,11,20-trione
-
-
17alpha,21-dihydroxy-4-pregnen-3,11,20-trione
-
-
17alpha-Hydroxy-4-androsten-3-one
-
-
17alpha-hydroxy-4-pregnen-3,20-dione
-
-
17alpha-Methyl-5alpha-dihydrotestosterone
-
-
17alpha-methyltestosterone
-
competitive inhibition
17beta-hydroxy-4-androsten-3-one
-
-
21-Hydroxy-5alpha-pregnan-3,20-dione
-
-
2alpha-Bromo-17beta-hydroxy-5alpha-androstan-3-one
2alpha-Bromo-5alpha-androstan-3,17-dione
-
-
2alpha-Cyano-17beta-methoxy-4-androsten-3-one
-
-
2alpha-Cyano-17beta-methoxy-5alpha-androstan-3-one
-
-
2alpha-Cyano-5alpha-dihydrotestosterone
-
-
2alpha-Fluoro-5alpha-androstan-3,17-dione
-
-
2alpha-Iodo-5alpha-androstan-3,17-dione
-
-
4-androsten-3,17-dione
-
-
4-Aza-4-methyl-5alpha-pregnane-3,20-dione
-
only slight inhibition
4-pregnen-3,20-dione
-
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
-
5alpha-Androstan-3,16-dione
-
-
5alpha-Androstan-3,17-dione
-
-
5alpha-Androstan-3-one
-
-
5alpha-Dihydrotestosterone hemisuccinate
-
-
5alpha-pregnan-3,20-dione
-
-
5beta-dihydrotestosterone
-
-
5beta-pregnan-3,20-dione
-
-
6alpha-Methylprednisolone
-
-
9-(phenylcarbonyl)-2,3,6,7-tetrahydro-1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinolin-11-one
-
competitive
acetaminophen
-
-
Arylpropionic acid
-
-
-
Bethamethasone
-
-
bromazepam
-
competitive inhibition of isozymes AKR1C1, AKR1C4, and AKR1C2
celecoxib
-
synthetic, nonsteroidal anti-inflammatory inhibitor, in vivo IC50: 0.050 mM in fluorometric assay, in vitro IC50: 0.050 mM in fluorometric assay
cholic acid
-
complete inhibition
cloxazolam
-
potent and specific, competitive inhibition of isozymes AKR1C1, AKR1C4, and AKR1C2
deoxycorticosterone
-
-
dexamethasone
dexamethasone 21-acetate
-
-
dexamethasone 21-hemisuccinate
-
-
diazepam
-
competitive inhibition of isozymes AKR1C1, AKR1C4, and AKR1C2
Dienstrol
-
-
estazolam
-
competitive inhibition of isozymes AKR1C1, AKR1C4, and AKR1C2
ethacrynate
-
-
ethynylestradiol
-
competitive inhibition
Fenamates
-
-
Flufenamic acid
flunitrazepam
-
competitive inhibition of isozymes AKR1C1 and AKR1C2
fluoxetine
-
allosteric interaction
Heavy metal ions
-
-
-
Hexestrol
-
-
Hg2+
-
-
Ibuprofen
-
synthetic, nonsteroidal anti-inflammatory inhibitor, in vivo IC50: 0.017 mM in fluorometric assay, in vitro IC50: 0.009 mM in fluorometric assay
indomethacin
Ketamine
-
inhibition of AKR1C17
medazepam
-
competitive inhibition of isozymes AKR1C1, AKR1C4, and AKR1C2
Medroxyprogesterone acetate
megestrol
-
competitive inhibition
Mg2+
-
strong inhibition of oxidation of 3alpha-hydroxysteroids
NADPH
naproxen
-
synthetic, nonsteroidal anti-inflammatory inhibitor, in vivo IC50: 0.0094 mM in fluorometric assay, 0.016 mM in radiometric assay, in vitro IC50: 0.0027 mM in fluorometric assay
nitrazepam
-
competitive inhibition of isozymes AKR1C1, AKR1C4, and AKR1C2
Norethindrone
-
-
p-chloromercuribenzoate
Phenolphthalein
-
AKR1C4-selective inhibitor, in vitro and in vivo inhibition, IC50: 0.0004 mM
Prednisolone
-
-
progesterone
-
-
prostaglandin A1
-
-
Prostaglandin D2
-
-
prostaglandin E2
-
-
prostaglandin F2alpha
-
-
Salicylates
-
-
-
Stilbestrol
-
-
sulfhydryl oxidizing reagents
-
-
-
testosterone
-
at concentration 0.001 mM 75% inhibition
tibolone
-
strong substrate inhibition of isozyme AKR1C2
Triamcinolone
-
-
ursodeoxycholate
Zomepirac
-
-
additional information
-